

CHIKUNGUNYA VACCINES

**ACIP Meeting
February 23, 2023**

**Beth Bell, MD, MPH
Chair, ACIP Chikungunya Vaccines Work Group**

Background

- Valneva completed submission of Biologics License Application (BLA) for their chikungunya vaccine to FDA in December 2022
- No chikungunya vaccine ever licensed in United States or globally
- No existing ACIP chikungunya vaccine recommendations
- Chikungunya Vaccines Work Group formed in May 2022 to develop policy options for ACIP's consideration for use of chikungunya vaccine among U.S. persons at risk of chikungunya, including
 - Travelers
 - Residents of U.S. territories and states with, or at risk of, transmission
 - Laboratory workers

Terms of Reference for Chikungunya Vaccines Work Group

- To review information on chikungunya disease, including outcomes
- To review data on chikungunya epidemiology and burden among U.S. residents, including travelers and persons living in areas at risk for local transmission
- To review data on safety, immunogenicity, and effectiveness of chikungunya vaccines
- To provide evidence-based recommendation options for ACIP
- To identify areas in need of further research for informing potential future vaccine recommendations
- To publish a chikungunya vaccine MMWR Recommendations and Reports document

Chikungunya Vaccines Work Group members

ACIP

Beth Bell, Univ Washington (Chair)

Wilbur Chen, Univ Maryland

CDC Leads

Susan Hills, DVBD (Lead)

Nicole Lindsey, DVBD (Deputy Lead)

Ex Officio

Robin Levis, FDA

Sixun Yang, FDA

Lesley Dupuy, NIH

ACIP Liaisons

Paschal Apanga, AIM

Elizabeth Barnett, ISTM

James Campbell, AAP

Mary Pat Friedlander, AAFP

Invited Consultants

Alan Barrett, Univ Texas Galveston

Carina Blackmore, Florida Dept Health

Alan Lam, DoD

Margaret Ryan, DoD

Steven Schofield, CATMAT

David Shlim, Jackson Hole Travel & Trop Med

Nestor Sosa, Uni New Mexico Hospital

Sanet Torres, San Jorge Children & Women's Hospital

Kirsten Vannice, Bill & Melinda Gates Foundation

Mary Wilson, Univ California San Francisco

Chikungunya Vaccines Work Group CDC participants

DVBD

Erin Staples

Ann Powers

Laura Adams

Joshua Wong

NCEZID

Rita Helfand

DGMQ

Sarah Guagliardo

DHQP

Michael McNeil

GID

Rebecca Casey

ISD

Elisabeth Velazquez

GRADE/ETR consultants

Doug Campos-Outcalt

Rebecca Morgan

ACIP Secretariat

Jessica MacNeil, NCIRD

Leslie Lee, NCIRD

Recap of previous Work Group presentations to ACIP

- October 2022
 - Overview of chikungunya virus disease and vaccines
 - Immunogenicity and safety of Valneva's chikungunya vaccine

Overview of today's session

- Global epidemiology of chikungunya
 - Dr. Susan Hills (CDC/NCEZID)
- Chikungunya in U.S. travelers
 - Ms. Nicole Lindsey (CDC/NCEZID)
- Persistent arthralgia following chikungunya
 - Ms. Nicole Lindsey (CDC/NCEZID)
- Work Group considerations
 - Ms. Nicole Lindsey (CDC/NCEZID)